{"id":"abt-925","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00412620"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2007","type":"negative","milestone":"Phase 2 Initiated","description":"An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophr — Schizophrenia. Trial terminated early."}],"aiSummary":"ABT-925 is an investigational compound that was evaluated in a Phase 2 trial for acute exacerbation of schizophrenia, with 156 subjects enrolled to assess safety and efficacy.","brandName":"ABT-925","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"ABT-925 is a drug that was being studied to help people who are experiencing a sudden worsening of schizophrenia symptoms. Schizophrenia is a condition where people may have trouble thinking clearly, feeling emotions normally, or relating to others. When symptoms get worse quickly, it is called an acute exacerbation. Researchers wanted to see if ABT-925 could help improve these symptoms and be safe for people to take during such times.","oneSentence":"ABT-925 is an experimental drug studied in people with worsening schizophrenia to see if it is safe and effective.","technicalDetail":"ABT-925 is an investigational compound that was evaluated in a Phase 2 clinical trial for the treatment of acute exacerbation of schizophrenia. The trial enrolled 156 subjects to assess the safety and efficacy of the drug in this population. Specific molecular targets, pathway mechanisms, or selectivity data for ABT-925 were not provided in the source text."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ABT-925","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00412620","phase":"Phase 2","title":"Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia","status":"TERMINATED","sponsor":"Abbott","isPivotal":false,"enrollment":156,"indication":"Schizophrenia","completionDate":"2007-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}